Table 1.

Tumour responses in 34 patients, 3 months after the final administration of ¹⁷⁷Lu-octreotate. Three patients with PD died before reaching their final dose

Tumour type	Response				Total
	CR	PR	SD	PD
Carcinoid		4 (33%)	6 (50%)	2 (17%)	12
NE pancreas	1 (8%)	1 (8%)	7 (58%)	3 (25%)	12
NE unknown origin		4 (57%)	1 (14%)	2 (29%)	7
Gastrinoma		3 (100%)			3
Total	1 (3%)	12 (35%)	14 (41%)	7 (21%)	34